LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

In Vitro Assay To Replace Animals in Genetic Toxicity Studies

By Biotechdaily staff writers
Posted on 24 May 2007
A recent publication described a high-throughput in-vitro assay for assessing a candidate drug's genetic toxicity that is expected to be cheaper and faster than existing animal tests.

Investigators at the Massachusetts Institute of Technology (MIT; Cambridge, USA) were trying to find a cell culture system that could replace the in-vivo erythroid micronucleus (MN) genotoxicity assay. This test requires injection of the drug compound into a live mouse. The new assay is based on adult red cell precursors taken from mouse bone marrow and grown in tissue culture. These precursor cells are suitable for this purpose, as they normally lose their nucleus during the last stage of red cell formation, and DNA-damaged precursors generate red blood cells containing an easily detected "micronucleus” consisting of fragments of nuclear DNA.

The in vitro assay allowed the precursor cells to proliferate and differentiate in the normal way, dividing four or five times before losing their nucleus and becoming immature red blood cells. Results obtained from the assay and published in the May 14, 2007, online edition of the Proceedings of the [U.S.] National Academy of Sciences revealed that adult bone marrow cultures responded to erythropoietin, the principal hormone that stimulates erythropoiesis, with physiologic erythropoietic proliferation, differentiation, and enucleation. The in-vitro erythropoietic system clearly signaled exposure to genotoxicants through erythroid MN formation. Responses to genotoxicants during erythroid differentiation varied with exposure time, demonstrating that this system could used to study the effect of DNA damage at specific developmental stages.

"This is a much cheaper assay that is at least as predictive as previous assays,” said senior author Dr. Linda Griffith, professor of biological engineering at MIT, "and drug developers can afford to use it a lot earlier in the drug development process.”


Related Links:
Massachusetts Institute of Technology

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gold Member
Hematology Analyzer
Medonic M32B

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
24 May 2007  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
24 May 2007  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
24 May 2007  |   BioResearch